Identical Mice, Different Gut Bacteria, Different Levels of Cancer

U-M study offers new clues about how the composition of the gut microbiome may contribute to the development of colorectal cancer.

11:38 AM

Author | Ian Demsky

Photo of researcher suited up holding tank with mouse inside.
Photo courtesy of ULAM Germ-Free Mouse Facility.

Researchers at the University of Michigan Rogel Cancer Center are shedding new light on the way microorganisms that live in the gastrointestinal tract can affect the development of colorectal cancer.

Some types of gut bacteria are better than others at stimulating certain immune cells, specifically CD8+ T cells, in the body, they found. And while these CD8+ T cells normally help protect the body against cancer, overstimulating them may promote inflammation and exhaust the T cells — which can actually increase susceptibility to cancer, according to new mouse model study published in Cell Reports.

The work will help scientists pinpoint which populations of bacteria are tumor suppressive or tumor promoting and how, says study first author Amy Yu, a doctoral candidate in immunology at U-M.

"There has also been a lot of excitement about the role bacteria may play in improving the effectiveness of immunotherapy," says senior study author Grace Chen, M.D., Ph.D., an associate professor of hematology/oncology at Michigan Medicine and member of the Rogel Cancer Center. "This work suggests it may be a double edged sword — and that promoting T cell exhaustion is something researchers need to watch out for."

In the U.S., colorectal cancer is the third-leading cause of cancer-related death in both men and women, according to the American Cancer Society.

Different mice, different outcomes

The current study builds on previous work from Chen's group, which found that disturbances of the gut microbiome can directly contribute to the development of cancer.

Our data ultimately revealed nine different bacterial populations that may have tumor-suppressive or tumor-promoting activity.
Amy Yu

The group found that mice from two different research colonies had vastly different susceptibility to colorectal cancer when they were exposed to a carcinogen as well as an agent that promotes gastrointestinal inflammation.

The mice from the first colony grew an average of five tumors, while the mice from the second colony developed 15 tumors and had a more significant inflammatory response.

When the researchers sequenced fecal bacteria from the two different colonies, they found they had distinct microbiomes composed of different types of bacteria.

"This was exciting because my lab is very interested in which bacteria have the biggest impact on colorectal cancer risk, and by what mechanisms," Chen says.

Same mice, different outcomes

To better understand what was causing the differences the researchers were seeing in the two different colonies of mice, they transplanted gut bacteria from each of the two colonies into genetically identical mice that had been bred in a bacteria free environment.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Once again, mice with bacteria from the second colony fared far worse.

"This showed that the different gut microbiota directly contributed to tumor development," Yu notes. "Our data ultimately revealed nine different bacterial populations that may have tumor-suppressive or tumor-promoting activity."

Investigating mechanisms

The team next conducted experiments to better understand what was driving the increased inflammation and tumor growth associated with the bacteria from the second mouse colony.

Through immune cell profiling, they found that there were more T cells in the colon tissue of mice with bacteria from the second colony, and many more of a type of cell called CD8+.

"It's a little counter intuitive, since T cells and CD8+ cells are usually associated with better outcomes in colorectal cancer patients," Chen says. "We hypothesized that these cells get over-activated in the presence of certain bacteria and then exhausted, leaving them less capable of killing tumor cells."

When the bacteria from the second mouse colony were transplanted into mice that were engineered to lack CD8+ T cells, fewer tumors developed, supporting T cells' role in promoting the growth of the cancer in the presence of certain bacteria, Chen notes.

Meanwhile, the lab continues to build on the research as it investigates the mechanisms by which different bacteria may contribute to promoting or protecting against the development of colorectal cancer.

Additional authors of the study include Lili Zhao, Kathryn A. Eaton, Sharon Ho, Jiachen Chen, Sara Poe, James Becker, Allison Gonzalez, Delaney McKinstry, Muneer Hasso, Jonny Mendoza-Castrejon, Joel Whitfield, Charles Koumpouras, Patrick D. Schloss and Eric C. Martens, all of U-M.

The research was funded by a U-M Rackham Research Grant, the National Institutes of Health (AI007413, CA166879), an American Cancer Society Research Scholar Grant, and the Tom Liu Memorial Golf Tournament Fund from the U-M Rogel Cancer Center.

Paper cited: "Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis," Cell Reports. DOI: 10.1016/j.celrep.2020.03.035

Like Podcasts? Add the Michigan Medicine News Break to your Alexa-enabled device or subscribe for updates on iTunesGoogle Play and Stitcher.


More Articles About: Lab Report Colorectal Cancer Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories
Health Lab
Gut Bacterium Jams Colorectal Cancer-Death Button
A new study finds Fusobacterium nucleatum promotes resistance to chemotherapy in colon cancer patients. Read more about gut bacterium, f. nucleatum and colorectal cancer.
Spilled pills next to a stethoscope and pile of cash
Health Lab
Drug pricing program improved prostate cancer treatment adherence
Socially vulnerable patients were more likely to stick with oral medications when treated at a hospital participating in 340B program, suggesting these hospitals may have more resources to help patients.
Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them
cancer cell blue yellow
Health Lab
Less chemoradiation is possible for some cancer patients
Some oropharynx cancer patients may qualify for less radiation treatments, according to a new study from experts at the University of Michigan Health Rogel Cancer Center.
cancer cell blue yellow
Health Lab
Targeted drug shows promising ability in treating rare head and neck cancers
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.